Condition: Venentoclax · Myeloid Malignancies · Conditioning · Sponsor: First Affiliated Hospital of Zhejiang University
Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) serves as a curative treatment modality for the vast majority of patients with hematological malignancies. Historically, due to the relatively high treatment-related mortality rate associated with Allo-HCT, this therapy was primarily administered to younger patients. However, the median age at onset of most hematological malignancies falls within the elderly population. For instance, the median ages at onset of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) are 68 and 77 years, respectively. In recent years, with the advancement of transplantation techniques and the application of Reduced-intensity Conditioning (RIC) regimens, a growing number of elderly patients have undergone Allo-HCT. Data from the Center for International Blood and Marrow Transplant Research (CIBMTR) indicate that in 2017, 31% of patients who received Allo-HCT were aged over 60 years, and 6% were over 70 years old. Over the past decade, the number of elderly patients undergoing Allo-HCT has increased significantly. Given that most elderly patients cannot tolerate conventional myeloablative conditioning regimens, RIC regimens based on Fludarabine (Flu) combined with Busulfan (Bu), or Fludarabine (Flu) combined with Melphalan (Mel) are currently widely used in elderly patients undergoing Allo-HCT. Nevertheless, the post-transplant relapse rate remains as high as 30%-55%, and the long-term GVHD-free and Relapse-free Survival (GRFS) ra…
This description comes directly from the study's public registry record.
Yi Luo, Professor · 0571 87233801 · luoyijr@zju.edu.cn
Panpan Zhu · +86 15825439779 · zhpanpan@zju.edu.cn
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Fujian Medical University | Fuzhou, Fujian, China | Recruiting |
| Nanfang Hospital Southern Medical University | Guangzhou, Guangdong, China | Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| Xiangya Hospital Central South University | Changsha, Hunan, China | Recruiting |
| Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University) | Nanjing, Jiangsu, China | Recruiting |
| Qilu Hospital of Shandong University | Jinan, Shandong, China | Recruiting |
| the First Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
| Zhejiang Cancer Hospital & Hangzhou Institute of Medicine, Chinese Academy of Sciences | Hangzhou, Zhejiang, China | Recruiting |
| Second Affiliated Hospital of Army Medical University (Xinqiao Hospital) | Chongqing, China | Recruiting |
| Sir Run Run Shaw Hospital Zhejiang University School of Medicine | Hangzhou, China | Recruiting |
| The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine) | Hangzhou, China | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07396480